PMID- 31708924
OWN - NLM
STAT- MEDLINE
DCOM- 20201006
LR  - 20201006
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 10
DP  - 2019
TI  - Dendritic Cells, the Double Agent in the War Against HIV-1.
PG  - 2485
LID - 10.3389/fimmu.2019.02485 [doi]
LID - 2485
AB  - Human Immunodeficiency Virus (HIV) infects cells from the immune system and has 
      thus developed tools to circumvent the host immunity and use it in its advance. 
      Dendritic cells (DCs) are the first immune cells to encounter the HIV, and being 
      the main antigen (Ag) presenting cells, they link the innate and the adaptive 
      immune responses. While DCs work to promote an efficient immune response and halt 
      the infection, HIV-1 has ways to take advantage of their role and uses DCs to 
      gain faster and more efficient access to CD4(+) T cells. Due to their ability to 
      activate a specific immune response, DCs are promising candidates to achieve the 
      functional cure of HIV-1 infection, but knowing the molecular partakers that 
      determine the relationship between virus and cell is the key for the rational and 
      successful design of a DC-based therapy. In this review, we summarize the current 
      state of knowledge on how both DC subsets (myeloid and plasmacytoid DCs) act in 
      presence of HIV-1, and focus on different pathways that the virus can take after 
      binding to DC. First, we explore the consequences of HIV-1 recognition by each 
      receptor on DCs, including CD4 and DC-SIGN. Second, we look at cellular 
      mechanisms that prevent productive infection and weapons that turn cellular 
      defense into a Trojan horse that hides the virus all the way to T cell. Finally, 
      we discuss the possible outcomes of DC-T cell contact.
CI  - Copyright (c) 2019 Martin-Moreno and Munoz-Fernandez.
FAU - Martin-Moreno, Alba
AU  - Martin-Moreno A
AD  - Seccion de Inmunologia, Laboratorio InmunoBiologia Molecular, Hospital General 
      Universitario Gregorio Maranon (HGUGM), Madrid, Spain.
AD  - Instituto Investigacion Sanitaria Gregorio Maranon (IiSGM), Madrid, Spain.
FAU - Munoz-Fernandez, M feminine Angeles
AU  - Munoz-Fernandez MA
AD  - Seccion de Inmunologia, Laboratorio InmunoBiologia Molecular, Hospital General 
      Universitario Gregorio Maranon (HGUGM), Madrid, Spain.
AD  - Instituto Investigacion Sanitaria Gregorio Maranon (IiSGM), Madrid, Spain.
AD  - Spanish HIV-HGM BioBank, Madrid, Spain.
AD  - Networking Research Center on Bioengineering, Biomaterials and Nanomedicine 
      (CIBER BBN), Madrid, Spain.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20191023
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
SB  - IM
MH  - CD4-Positive T-Lymphocytes/virology
MH  - Dendritic Cells/*immunology/virology
MH  - HIV Infections/*immunology/therapy/virology
MH  - HIV-1/*immunology
MH  - Humans
MH  - Immunotherapy
PMC - PMC6820366
OTO - NOTNLM
OT  - HIV-1
OT  - cis-infection
OT  - dendritic cells
OT  - endocytosis
OT  - immune response
OT  - trans-infection
EDAT- 2019/11/12 06:00
MHDA- 2020/10/07 06:00
PMCR- 2019/01/01
CRDT- 2019/11/12 06:00
PHST- 2019/07/03 00:00 [received]
PHST- 2019/10/04 00:00 [accepted]
PHST- 2019/11/12 06:00 [entrez]
PHST- 2019/11/12 06:00 [pubmed]
PHST- 2020/10/07 06:00 [medline]
PHST- 2019/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2019.02485 [doi]
PST - epublish
SO  - Front Immunol. 2019 Oct 23;10:2485. doi: 10.3389/fimmu.2019.02485. eCollection 
      2019.